Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study)
Arthritis Rheumatol. 2020 Sep; 72(9): 1435–1446.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Arthritis Rheumatol. 2020 Sep; 72(9): 1435–1446.
Z Rheumatol. 2020 DOI: 10.1007/s00393-020-00750-1
JAMA Dermatol 2020;156:649–58. doi 10.1001/jamadermatol.2020.0723
Blauvelt et al. shows superior and sustained efficacy for risankizumab in maintaining skin clearance over time versus placebo upon withdrawal, alongside a favourable safety profile in chronic plaque psoriasis through a phase 3, randomised, double-blind, placebo-controlled study, assessing PASI 90 and sPGA score of 0/1 at Week 16.
Ther Adv Musculoskelet Dis. 2020;12:1759720X19899296
Clin Transl Sci . 2020 Mar;13(2):325-336. doi: 10.1111/cts.12713. Epub 2019 Nov 29.
Please click the links below to go to the CSF review of each paper
Clin Pharmacol Ther . 2020 Apr;107(4):994-1003. doi: 10.1002/cpt.1671.
Clin Drug Investig .2020 Jan;40(1):65-72. doi: 10.1007/s40261-019-00863-9.
Arthritis Res Ther. 2019 Aug 2;21(1):183
Ann Rheum Dis 2019 DOI: 10.1136/annrheumdis-2019-215164